Management and Survival of Elderly and Very Elderly Patients with Ovarian Cancer An Age-Stratified Study of 1123 Women from the FRANCOGYN Group - Centre Georges Francois Leclerc Accéder directement au contenu
Article Dans Une Revue Journal of Clinical Medicine Année : 2020

Management and Survival of Elderly and Very Elderly Patients with Ovarian Cancer An Age-Stratified Study of 1123 Women from the FRANCOGYN Group

Sofiane Bendifallah
  • Fonction : Auteur
Camille Mimoun
  • Fonction : Auteur
Alexandre Bricou
  • Fonction : Auteur
Pierre Collinet
  • Fonction : Auteur
Cyril Touboul
  • Fonction : Auteur
Lobna Ouldamer
Henri Azaïs
Yohann Dabi
  • Fonction : Auteur
Cherif Akladios
  • Fonction : Auteur
Geoffroy Canlorbe
  • Fonction : Auteur
Pierre-Adrien Bolze
Mathieu Mezzadri
  • Fonction : Auteur
Tristan Gauthier
  • Fonction : Auteur
Frederic Kridelka
  • Fonction : Auteur
Pauline Chauvet
  • Fonction : Auteur
Nicolas Bourdel
  • Fonction : Auteur
Martin Koskas
  • Fonction : Auteur
Xavier Carcopino
  • Fonction : Auteur
Emilie Raimond
  • Fonction : Auteur
Olivier Graesslin
  • Fonction : Auteur
Lise Lecointre
  • Fonction : Auteur
Marcos Ballester
  • Fonction : Auteur
Cyrille Huchon

Résumé

Elderly women with ovarian cancer are often undertreated due to a perception of frailty. We aimed to evaluate the management of young, elderly and very elderly patients and its impact on survival in a retrospective multicenter study of women with ovarian cancer between 2007 to 2015. We included 979 women 615 women (62.8%) <65 years, 225 (22.6%) 65-74 years, and 139 (14.2%) ≥75 years. Women in the 65-74 years age group were more likely to have serous ovarian cancer (p = 0.048). Patients >65 years had more >IIa FIGO stage 76% for <65 years, 84% for 65-74 years and 80% for ≥75 years (p = 0.033). Women ≥75 years had less standard procedures (40% (34/84) vs. 59% (104/177) for 65-74 years and 72% (384/530) for <65 years (p < 0.001). Only 9% (13/139) of women ≥75 years had an Aletti score >8 compared with 16% and 22% for the other groups (p < 0.001). More residual disease was found in the two older groups (30%, respectively) than the younger group (20%) (p < 0.05). Women ≥75 years had fewer neoadjuvant/adjuvant cycles than the young and elderly women 23% ≥75 years received <6 cycles vs. 10% (p = 0.003). Univariate analysis for 3-year Overall Survival showed that age >65 years, FIGO III (HR = 3.702, 95%CI 2.30-5.95) and IV (HR = 6.318, 95%CI 3.70-10.77) (p < 0.001), residual disease (HR = 3.226, 95%CI 2.51-4.15; p < 0.001) and lymph node metastasis (HR = 2.81, 95%CI 1.91-4.12; p < 0.001) were associated with lower OS. Women >65 years are more likely to have incomplete surgery and more residual disease despite more advanced ovarian cancer. These elements are prognostic factors for women's survival regardless of age. Specific trials in the elderly would produce evidence-based medicine and guidelines for ovarian cancer management in this population.
Fichier principal
Vignette du fichier
jcm-09-01451-v2.pdf (835.58 Ko) Télécharger le fichier
Origine : Publication financée par une institution
Loading...

Dates et versions

hal-02860104 , version 1 (17-07-2020)

Licence

Paternité

Identifiants

Citer

Yolaine Joueidi, Ludivine Dion, Sofiane Bendifallah, Camille Mimoun, Alexandre Bricou, et al.. Management and Survival of Elderly and Very Elderly Patients with Ovarian Cancer An Age-Stratified Study of 1123 Women from the FRANCOGYN Group. Journal of Clinical Medicine, 2020, 9 (5), ⟨10.3390/jcm9051451⟩. ⟨hal-02860104⟩
29 Consultations
57 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More